IL6 and neoplasm: Interleukin 17A (IL-17A), a pro-inflammatory cytokine secreted by CD4+ Th17 cells, triggers tumor cells to produce interleukin 6 (IL-6), which in turn activates STAT3-dependent survival and angiogenesis [43].